XTL Biopharmaceuticals (XTLB)

• Market cap: $7.22M
• 1 day: 1.38%
• 5 days: 6.91%
• 1 month: 5.38%
• 3 months: 20.99%
• 6 months: -22.83%
• Year to date: 22.5%
• 1 year: -58%
• 5 years: -79.58%
• 10 years: -86.76%
• Sector: Healthcare
• Industry: Biotechnology

About: XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.

Employees: 2